Expert consensus on the detection and clinical management of familial hypercholesterolemia;Consenso de expertos sobre la detección y el manejo clínico de la hipercolesterolemia familiar

Clinica e Investigacion en Arteriosclerosis

Volumn 25, Issue 4, 2013, Pages 182-193

  Masana, Lluís ^a   Civeira, Fernando ^a   Pedro Botet, Juan ^a   de Castro, Isabel ^a   Pocoví, Miguel ^a   Plana, Núria ^a   Mateo Gallego, Rocío ^a   Jarauta, Estíbaliz ^a   Pedragosa, Àngels ^a  

^a Sociedad Española de Arteriosclerosis ^*  (Spain)

Author keywords

Clinical management; Familial hypercholesterolemia; Guidelines

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR SYSTEM EXAMINATION; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; MEDICAL INFORMATION; PRACTICE GUIDELINE; PROGNOSIS; SPAIN;

CLINICAL MANAGEMENT; DIRECTRICES; FAMILIAL HYPERCHOLESTEROLEMIA; GUIDELINES; HIPERCOLESTEROLEMIA FAMILIAR; MANEJO CLÍNICO;

CHOLESTEROL, LDL; EARLY DIAGNOSIS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SOCIETIES, MEDICAL; SPAIN;

EID: 84887023781     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/j.arteri.2013.07.005     Document Type: Article

References (47)

1. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. The Metabolic and Molecular Bases of Inherited Disease 2001, 2863-2913. McGraw-Hill, New York. C.R. Scriver, A.L. Baudet, W.S. Sly, D. Valle, B. Childs, K.W. Kinzler (Eds.).
2. Goldstein J.L., Brown M.S. Familial hypercholesterolemia: Identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci U S A 1973, 70:2084-2088.
3. Marduel M., Ouguerram K., Serre V., Bonnefont Rousselot D., Marques-Pinheiro A., Erik Berge K., et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat 2013, 34:83-87.
4. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004, 173:55-68. International Panel on Management of Familial Hypercholesterolemia.
5. Palacios L., Grandoso L., Cuevas N., Olano-Martín E., Martinez A., Tejedor D., et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis 2012, 221:137-142.
6. Rader D.J., Cohen J., Hobbs H.H. Monogenic hypercholesterolemia: New insights in pathogenesis and treatment. J Clin Invest 2003, 111:1795-1803.
7. Junyent M., Gilabert R., Jarauta E., Núñez I., Cofán M., Civeira F., et al. Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis 2010, 208:437-441.
8. Innerarity T.L., Weisgraber K.H., Arnold K.S., Mahley R.W., Krauss R.M., Vega G.L., et al. Familial defective apolipoprotein B-100: Low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A 1987, 84:6919-6923.
9. Marais D.A., Blom D.J., Petrides F., Gouëffic Y., Lambert G. Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidol 2012, 23:511-517.
10. Talmud P.J., Shah S., Whittall R., Futema M., Howard P., Cooper J.A., et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study. Lancet 2013, 381:1293-1301.
11. Humphries S.E., Whittall R.A., Hubbart C.S., Maplebeck S., Cooper J.A., Soutar A.K., et al. Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Genetic causes of familial hypercholesterolaemia in patients in the UK: Relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006, 43:943-949.
12. Civeira F., Ros E., Jarauta E., Plana N., Zambon D., Puzo J., et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008, 102:1187-1193.
13. Junyent M., Gilabert R., Zambón D., Núñez I., Vela M., Civeira F., et al. The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscler Thromb Vasc Biol 2005, 25:2203-2208.
14. Alonso R., Mata N., Castillo S., Fuentes F., Saenz P., Muñiz O., et al. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008, 200:315-321. Spanish Familial Hypercholesterolaemia Group.
15. Austin M.A., Hutter C.M., Zimmern R.L., Humphries S.E. Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review. Am J Epidemiol 2004, 160:407-420.
16. McCrindle B.W. Familial hypercholesterolemia in children and adolescents. Curr Opin Lipidol 2012, 23:525-531.
17. Wierzbicki A.S., Humphries S.E., Minhas R. Familial hypercholesterolemia: Summary of NICE guidance. BMJ 2008, 337:a1095. on behalf of the Guideline Development Group.
18. Descamps O.S., Tenoutasse S., Stephenne X., Gies I., Beauloye V., Lebrethon M.C., et al. Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011, 218:272-280.
19. Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G., et al. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011, 5(Suppl. 3):S1-S8.
20. Robinson J.G., Goldberg AC Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011, 5(Suppl. 3):S18-S29. National Lipid Association Expert Panel on Familial Hypercholesterolemia.
21. Catapano A.L., Reiner Z., de Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS).
22. Elis A., Zhou R., Stein E.A. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J Cardiol 2011, 108:223-226.
23. Sibley C., Stone N.J. Familial hypercholesterolemia: a challenge of diagnosis and therapy. Cleve Clin J Med 2006, 73:57-64.
24. Ito M.K., McGowan M.P., Moriarty P.M. Management of familial hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011, 5:S38-S45.
25. Neil A., Cooper J., Betteridge J., Capps N., McDowell I., Durrington P., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: A prospective registry study. Eur Heart J 2008, 29:2625-2633.
26. Versmissen J., Oosterveer D.M., Yazdanpanah M., Defesche J.C., Basart D.C., Liem A.H., et al. Efficacy of statins in familial hypercholesterolaemia: A long-term cohort study. BMJ 2008, 337:a2423.
27. Hoffman K.B., Kraus C., Dimbil M., Golomb B.A. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One 2012, 7:e42866.
28. Stein E., Stender S., Mata P., Sager P., Ponsonnet D., Melani L., et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004, 148:447-455. Ezetimibe Study Group.
29. Huijgen R., Abbink E.J., Bruckert E., Stalenhoef A.F., Imholz B.P., Durrington P.N., et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: A 12- week, multicenter, randomized, double-blind, controlled trial. Clin Ther 2010, 32:615-625. Triple Study Group.
30. Huijgen R., Kindt I., Verhoeven S.B., Sijbrands E.J., Vissers M.N., Kastelein J.J., et al. Two years after molecular diagnosis of familial hypercholesterolemia: Majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010, 5:e9220.
31. Pijlman A.H., Huijgen R., Verhagen S.N., Imholz B.P., Liem A.H., Kastelein J.J., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands. Atherosclerosis 2010, 209:189-194.
32. Winters J.L. Low-density lipoprotein apheresis: Principles and indications. Semin Dial 2012, 25:145-151.
33. Arbona C., Martinez-Hervás S., Goterris R., Montoro J., Real J.T., Ascaso J.F. Aféresis de lipoproteínas de baja densidad en la hipercolesterolemia familiar resistente al tratamiento médico convencional intensivo. Med Clin (Barc) 2013, 140:207-210.
34. Shafiq N., Singh M., Kaur S., Khosla P., Malhotra S. Dietary treatment for familial hypercholesterolaemia. Cochrane Database Syst Rev 2010, 1:CD001918.
35. Obarzanek E., Kimm S.Y., Barton B.A., van Horn L., Kwiterovich P.O., Simons-Morton D.G., et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: Seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics 2001, 107:256-264. DISC Collaborative Research Group.
36. Guardamagna O., Abello F., Baracco V., Federici G., Bertucci P., Mozzi A., et al. Primary hyperlipidemias in children: Effect of plant sterol supplementation on plasma lipids and markers of cholesterol synthesis and absorption. Acta Diabetol 2011, 48:127-133.
37. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary report. Pediatrics 2011, 128(Suppl. 5):S213-S256.
38. Vuorio A., Kuoppala J., Kovanen P.T., Humphries S.E., Strandberg T., Tonstad S., et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2010, 7:CD006401.
39. Daniels S.R., Gidding S.S., de Ferranti S.D. Pediatric aspects of familial hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J ClinLipidol 2011, 5:S30-S37.
40. Rodenburg J., Vissers M.N., Wiegman A., van Trotsenburg A.S., van der Graaf A., de Groot E., et al. Statin treatment in children with familial hypercholesterolemia: The younger, the better. Circulation 2007, 116:664-668.
41. Vuorio A., Docherty K.F., Humphries S.E., Kuoppala J., Kovanen P.T. Statin treatment of children with familial hypercholesterolemia - Trying to balance incomplete evidence of long-term safety and clinical accountability: Are we approaching a consensus. Atherosclerosis 2013, 226:315-320.
42. Van der Graaf A., Cuffie-Jackson C., Vissers M.N., Trip M.D., Gagné C., Shi G., et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008, 52:1421-1429.
43. Araujo M.B., Botto P.M., Mazza C.S. Uso de ezetimiba en el tratamiento de la hipercolesterolemia familiar en niños y adolescentes. An Pediatr (Barc) 2012, 77:37-42.
44. Carreau V., Girardet J.P., Bruckert E. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: Efficacy and tolerability. Paediatr Drugs 2011, 13:267-275.
45. Toleikyte I., Retterstøl K., Leren T.P., Iversen P.O. Pregnancy outcomes in familial hypercholesterolemia: A registry-based study. Circulation 2011, 124:1606-1614.
46. Eapen D.J., Valiani K., Reddy S., Sperling L. Management of familial hypercholesterolemia during pregnancy: Case series and discussion. J Clin Lipidol 2012, 6:88-91.
47. Perk J., de Backer G., Gohlke H., Graham I., Reiner Z., Verschuren W.M., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012, 223:1-68. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice; European Association for Cardiovascular Prevention and Rehabilitation.